Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through ...

Verona Pharma (NASDAQ:VRNA – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $60.00 price target ...

And I predict that 2025 will be another momentous year for Summit. Summit already owned the license to market ivonescimab in ...

Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on Verona Pharma (VRNA) to $60 from $42 and keeps a Buy rating on the ...

On Tuesday, H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares. The ...

On Tuesday, H.C. Wainwright analyst increased the price target on shares of Verona Pharma (NASDAQ:VRNA) to $60 from the previous target of $42, maintaining a Buy rating on the shares. The adjustment ...

To participate, please dial one of the following numbers and ask to join the Verona Pharma call: Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.